Skip to main content
. 2018 Aug 7;2(15):1901–1913. doi: 10.1182/bloodadvances.2018020966

Table 4.

Comparison of adjusted overall survival probabilities with primary cancer patients in the general population

Cancer type No. 3-y adjusted overall survival* Autologous vs general Allogeneic vs general
General Autologous Allogeneic General Autologous Allogeneic HR* (95% CI) P HR* (95% CI) P
All 541 134 217 496 0.72 0.65 0.60 1.21 (0.96-1.53) .11 1.41 (1.20-1.65) <.001
Oral cavity/pharynx 7 904 8 109 0.65 0.85 0.62 0.55 (0.08-3.93) .56 0.99 (0.65-1.49) .95
Esophagus 13 804 7 76 0.42 0.47 0.34 0.61 (0.15-2.44) .48 1.15 (0.83-1.60) .40
Stomach 82 076 20 28 0.66 0.54 0.57 1.61 (0.76-3.37) .21 1.37 (0.65-2.87) .41
Colon 72 270 36 43 0.75 0.63 0.54 1.57 (0.85-2.92) .15 2.14 (1.27-3.62) .004
Liver 32 078 14 6 0.45 0.47 0.44 0.95 (0.43-2.12) .91 1.32 (0.42-4.10) .63
Pancreas 11 329 10 15 0.12 0.20 0.07 0.81 (0.34-1.95) .64 1.24 (0.67-2.31) .49
Lung 63 833 38 43 0.38 0.42 0.28 0.88 (0.55-1.42) .60 1.12 (0.73-1.72) .61
Bone/soft tissue 2 404 9 22 0.67 0.21 0.24 2.93 (1.21-7.07) .017 3.16 (1.68-5.93) <.001
Skin 5 582 4 24 0.88 NA 0.92 NA NA 0.60 (0.08-4.27) .61
Breast 50 155 14 24 0.93 0.91 0.90 1.35 (0.19-9.57) .77 0.99 (0.14-7.07) 1.0
Cervix uteri 6 459 1 8 0.81 NA 0.61 NA NA 2.71 (0.67-10.9) .16
Corpus uteri 7 298 4 9 0.87 NA 0.86 NA NA 1.59 (0.22-11.5) .65
Prostate 18 481 12 10 0.91 1.00 0.81 NA NA 3.26 (0.46-23.2) .24
Kidney 9 051 10 5 0.76 0.83 0.22 0.63 (0.09-4.51) .65 2.27 (0.32-16.1) .41
Bladder 6 959 7 12 0.78 1.00 0.72 NA NA 0.74 (0.10-5.27) .76
Central nervous system 750 2 14 0.27 NA 0.01 NA NA 4.54 (2.29-9.01) <.001
Thyroid 9 507 6 22 0.97 0.94 0.84 2.01 (0.27-14.8) .49 4.47 (0.63-31.9) .14

NA, not applicable.

*

Adjusted for patient sex, patient age at cancer diagnosis, year of cancer diagnosis, and cancer type. Hazard ratios and P values were derived from multivariable Cox models.